Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABEOOTCMKTS:NWBONASDAQ:OASMNASDAQ:SESNNASDAQ:TOCA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$3.19+0.6%$7.37$2.83▼$9.01$87.25M1.49432,179 shs1.10 million shsNWBONorthwest Biotherapeutics$0.48+4.4%$0.53$0.40▼$1.09$574.33M-0.681.72 million shs1.10 million shsOASMOasmia Pharmaceutical AB (publ)$0.02$1.46$0.94▼$5.70$1.50M0.9698,414 shsN/ASESNSesen Bio$10.50$0.37▼$12.58$2.56B0.831.07 million shs93,330 shsTOCATocagen$0.74+2.8%$32.24$0.42▼$6.77$17.68M0.011.47 million shs2,845 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics+0.63%-57.64%-56.66%-31.98%-0.31%NWBONorthwest Biotherapeutics+3.67%-6.47%-10.17%-20.10%-3.64%OASMOasmia Pharmaceutical AB (publ)0.00%0.00%0.00%0.00%-60.00%SESNSesen Bio0.00%0.00%0.00%0.00%0.00%TOCATocagen+2.65%-5.26%+4.08%-1.11%-29.62%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABEOAbeona Therapeutics3.6416 of 5 stars3.51.00.04.51.61.70.6NWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics3.00Buy$36.001,028.53% UpsideNWBONorthwest BiotherapeuticsN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/ACurrent Analyst RatingsLatest TOCA, OASM, NWBO, SESN, and ABEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024ABEOAbeona TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$36.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M24.93N/AN/A$0.60 per share5.32NWBONorthwest Biotherapeutics$1.93M297.58N/AN/A($0.06) per share-7.95OASMOasmia Pharmaceutical AB (publ)$220K6.82N/AN/A$0.63 per share0.03SESNSesen Bio$40M0.00N/A3.39$0.78 per share0.00TOCATocagen$40K441.90N/AN/A$0.45 per share1.64Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$54.19M-$2.58N/AN/AN/AN/A-280.58%-76.90%5/9/2024 (Estimated)NWBONorthwest Biotherapeutics-$62.60M-$0.06N/A∞N/A-3,240.11%N/A-207.51%5/8/2024 (Estimated)OASMOasmia Pharmaceutical AB (publ)-$18.95MN/A0.00∞N/A-8,633.64%-43.94%-28.92%N/ASESNSesen Bio-$19.88M-$0.10N/AN/AN/AN/A6.70%5.41%N/ATOCATocagen-$63.52M-$2.69N/AN/AN/A-176,433.34%-327.74%-111.87%N/ALatest TOCA, OASM, NWBO, SESN, and ABEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023ABEOAbeona Therapeutics-$0.51-$0.64-$0.13-$0.64N/AN/A3/5/2024Q4 2023NWBONorthwest BiotherapeuticsN/A-$0.02-$0.02-$0.02N/A$0.45 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona TherapeuticsN/A4.154.15NWBONorthwest BiotherapeuticsN/A0.090.09OASMOasmia Pharmaceutical AB (publ)N/A0.800.73SESNSesen BioN/A6.106.10TOCATocagen1.881.151.15OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%NWBONorthwest Biotherapeutics0.04%OASMOasmia Pharmaceutical AB (publ)0.11%SESNSesen Bio16.45%TOCATocagen21.42%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.30%NWBONorthwest Biotherapeutics9.40%OASMOasmia Pharmaceutical AB (publ)N/ASESNSesen Bio3.20%TOCATocagen10.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona TherapeuticsN/A27.35 million25.91 millionOptionableNWBONorthwest Biotherapeutics251.20 billion1.09 billionNot OptionableOASMOasmia Pharmaceutical AB (publ)5774.97 millionN/ANot OptionableSESNSesen Bio35203.49 million196.98 millionOptionableTOCATocagen7723.92 millionN/ANot OptionableTOCA, OASM, NWBO, SESN, and ABEO HeadlinesSourceHeadlineGlioblastoma Treatment Market Expected to Reach USD 10.3 Billion by 2032 | Marketresearch.bizpharmiweb.com - March 25 at 4:25 AMONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Gliomaascopubs.org - February 12 at 6:14 PMMiami Cancer Institute publication analyzes role of tissue-agnostic therapies for the treatment of primary brain tumorseurekalert.org - January 20 at 12:14 AMForte Biosciences: Changes In Registrant S Certifying Accountantcbonds.com - December 12 at 8:27 AMRiskOn International And 3 Other Stocks Under $2 Insiders Are Buyingmarkets.businessinsider.com - December 11 at 9:20 AMPrecision and personalized medicine: the leading companies in personalized cancer vaccines revealedpharmaceutical-technology.com - November 6 at 9:33 AMProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board Appointmentfinance.yahoo.com - November 2 at 10:33 AMFDA Clears Phase II Trial of Denovo Biopharma Gene Therapy in Glioma Patientsprecisionmedicineonline.com - July 26 at 11:09 PMGene Therapy Market Report 2023 Provides SWOT Analysis ... - openPRnews.google.com - May 12 at 8:33 AMForm DEF 14A CTI BIOPHARMA CORP For: Jun 21 - StreetInsider.comnews.google.com - April 29 at 12:45 AMGenomic and transcriptomic analysis of checkpoint blockade ... - Nature.comnews.google.com - April 6 at 8:25 PMBelzutifan plus cabozantinib for patients with advanced clear cell ... - The Lancetnews.google.com - March 31 at 11:10 PMCurrent drug development and trial designs in neuro-oncology ... - The Lancetnews.google.com - March 28 at 12:07 AMCompanion Diagnostics Market is set to experience a significant ... - Digital Journalnews.google.com - March 27 at 8:37 AMOligodendroglioma Pipeline Drugs and Companies Insight Report ... - Digital Journalnews.google.com - March 14 at 4:44 PMAnaplastic Astrocytoma Drug Market| Global Industry Analysis ... - Digital Journalnews.google.com - March 8 at 10:39 AMAnaplastic Oligoastrocytoma Market Focus On Estimation, Research ... - Taiwan Newsnews.google.com - March 2 at 1:05 PMAnaplastic Oligoastrocytoma Market Industry Analysis, Estimates Size and Projections by 2029marketwatch.com - February 28 at 3:22 AMCompanion Diagnostics Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2029marketwatch.com - February 27 at 9:31 AMAn echo through brain cancer’s empty pipelinepharmaphorum.com - February 7 at 7:04 PMCompanion Diagnostics Market Size, Share, Growth Statistics By ... - Digital Journalnews.google.com - February 3 at 6:12 AMCardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer - Yahoo Financenews.google.com - February 2 at 1:10 PMCardiff Oncology Announces the Appointment of Fairooz Kabbinavar ... - PR Newswirenews.google.com - February 2 at 8:09 AMHuman Resource Management Market Booming Worldwide With ... - Rejoice Magazinenews.google.com - January 27 at 11:36 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAbeona TherapeuticsNASDAQ:ABEOAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Northwest BiotherapeuticsOTCMKTS:NWBONorthwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.Oasmia Pharmaceutical AB (publ)NASDAQ:OASMOasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.Sesen BioNASDAQ:SESNSesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.TocagenNASDAQ:TOCATocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.